Cannabix Technologies to Attend
U.S. National Drug and Alcohol Conference to Market Marijuana
Breath Test
Vancouver, British Columbia, Canada -- April 1, 2025 -- Cannabix
Technologies Inc. (CSE:
BLO) (OTC
PINK: BLOZF) (Frankfurt: 8CT) (the "Company or Cannabix")
developer of marijuana and alcohol breath testing devices is
pleased to report that it will be
attending the National Drug and Alcohol
Screening Association (NDASA)
conference in Florida in early April alongside strategic partner,
Omega Laboratories, to begin joint marketing of the Company's
Marijuana Breath Test (MBT). NDASA is one of world's largest organizations
providing education and resources for workplace safety.
The conference will be attended by
corporations and professionals in the drug and alcohol testing
industry from around the world. This comes on the heels of a
laboratory validation milestone with the Cannabix Marijuana Breath Test
by strategic partner Omega
Laboratories ("Omega").
Highlights:
- Omega
Laboratories of Ohio, USA, recently announced the development and
validation of the Cannabix Marijuana Breath Test;
- The
validation included test method for the simultaneous quantification
of Delta-9-tetrahydrocannabinol (THC), Delta-8-THC,
cannabidiol (CBD), and cannabinol (CBN) in breath aerosols using
the Cannabix Breath Collection Unit (BCU) and Breath Cartridge (BC)
(combined, referred to as the "MBT", see Figure 1);
-
Cannabix and Omega will attend NDASA in early April. This is a premier event
in the U.S. for the drug and alcohol testing industry.
-
Cannabix's MBT is a collect and send solution, focused on
"recent use" detection of delta-9 THC as opposed to urine, blood
and saliva methods (that can detect delta-9 THC many hours, days,
or even weeks after consumption) (1)
-
The
Company is advancing an operational review to meet manufacturing,
human resources, sales, marketing, support and order fulfilment
needs that are expected to grow.
Figure 1. Cannabix Breath
Collection Unit with Breath Cartridge technology.
On March 18th,
Omega, a leading drug testing laboratory with facilities in
the United States and Canada, announced the development and validation
of the Cannabix Marijuana Breath
Test. The validation included a test method for the
simultaneous quantification of Delta-9-tetrahydrocannabinol
(THC), Delta-8-THC,
cannabidiol (CBD), and cannabinol (CBN) in breath aerosols
collected using Cannabix's BCU and BC hardware. This development
establishes Omega and Cannabix as new technology offering for
collecting and testing breath for recent marijuana usage. Omega
Laboratories is currently in the process of incorporating
Cannabix's breath testing technology into its suite of services and
integrating testing protocols. The Company is advancing an
operational review to meet demands that are anticipated to
grow.
Rav Mlait, CEO of
Cannabix stated, "In the United States, cannabis legalization has
grown to 39 states for medical use
and 24 states legalized for recreational use. Cannabix is at
the forefront of drug detection using human breath. Omega
Laboratories' validation work is a major milestone for the Company
and its history of cutting-edge breath research and development. I
want to commend the work of both Omega and Cannabix staff,
scientists and engineers."
(1)
Olla P, Ishraque MT, Bartol S. 2020. Evaluation of Breath and
Plasma Tetrahydrocannabinol Concentration Trends Postcannabis
Exposure in Medical Cannabis Patients. Cannabis and Cannabinoid
Res.; 99-104.
Swortwood MJ, Newmeyer MN, Andersson M, Abulseoud OA, Scheidweiler
KB, Huestis MA. 2017. Cannabinoid disposition in oral fluid after
controlled smoked, vaporized, and oral cannabis administration.
Drug Testing and Analysis, 9(6), 905–915.
Musshoff F & Madea B. 2006. Review of biologic matrices (urine,
blood, hair) as indicators of recent or ongoing cannabis use. Ther
Drug Monit. 28(2),155-63.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol
breath testing technologies for a range of workplaces, law
enforcement and other settings. Breath testing for delta-9 THC (the
primary psychoactive ingredient in
cannabis) would allow employers and law enforcement
to identify recent marijuana use. Cannabix is the developer of
the Breath Logix autonomous
alcohol screening device for organizations who strive to improve
alcohol safety and monitoring.
We seek Safe
Harbor.
On behalf of the Board of Directors
"Rav Mlait"
CEO
Cannabix
Technologies Inc.
For further
information, contact the Company at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept
responsibility for the adequacy or accuracy of this
release.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain
"forward-looking statements" within the meaning of such statements
under applicable securities law. Forward-looking statements are
frequently characterized by words such as "anticipates," "plan,"
"continue," "expect," "project," "intend," "believe," "anticipate,"
"estimate," "may," "will," "potential," "proposed," "positioned"
and other similar words, or statements that certain events or
conditions "may" or "will" occur. Forward-looking statements in
this news release include, but are not limited to, statements
relating to: certification of devices, acceptance of devices by
international regulators, the achievement of any or all of the
goals and aims of the strategic
partnership and development agreement with Omega Laboratories; the
completion of pre-validation or validation testing described in
this news release; final development of a commercial or prototype
product(s); the successful trial or pilot of company technologies;
the commercialization of the Company's products; the negotiation
and potential entry into additional agreements with distributors;
and the completion of future financings. There are numerous risks
and uncertainties that could cause actual results and the Company's
plans and objectives to differ materially from those expressed in
the forward-looking information. Important factors that could cause
actual results to differ materially from those expressed in the
forward-looking information include (but are note limited to):
adverse market conditions; risks regarding protection of
proprietary technology; the ability of the Company to complete
future financings; the ability of the Company to develop and market
its future product; risks regarding government regulation, managing
and maintaining growth, the effect of adverse publicity,
litigation, competition; that Omega may not complete all or any of
the milestones as contemplated strategic partnership and
development agreement with Omega Laboratories; that the CSE may not
approve the issuance of the securities; that the Company's
development of breathalyzer technology will provide any benefit to
the Company; there is no assurance that any proposed new products
will be built, will be successful in beta testing or clinical
trials; there is no assurance that the Company will enter into any
partnerships to advance any of its corporate initiatives or
technologies; there is no assurance that any "patent pending" or
"provisional patents" technologies licensed by the Company or owned
by the Company will receive patent status by regulatory
authorities; the Company is not currently selling breathalyzers and
there is no assurance that the Company ever will; and other factors
beyond the control of the Company. Actual results and future events
could differ materially from those anticipated in such information.
These and all subsequent written and oral forward-looking
information are based on estimates and opinions of management on
the dates they are made and are expressly qualified in their
entirety by this notice. Except as required by law, the Company
does not intend to update these forward-looking
statements.
501-3292 Production Way, Burnaby, B.C., V5A 4R4
Phone: (604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com